Role of anti miasmatic medicines in the cases of male androgenetic alopecia in age group of 15-30 years
试验速览
- 阶段
- 2/3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Androgenetic alopecia will be assessed with Trichoscopic examination
研究概览
简要总结
THIS STUDY IS PROSPECTIVE STUDY PRE TEST POST TEST ONE GROUP EXPERIMENTAL STUDY TO ASSESS THE ROLE OF ANTI MIASMATIC MEDICINES FOR 10 MONTHS IN 40 PARTICIPANT WITH MALE ANDROGENETIC ALOPECIA THAT WILL BE CONDUCTED AS PER INCLUSION AND EXCLUSION CRITERIA FROM OUT PATIENT DEPARTMENT AND THE PRIMARY OUTCOME MEASURE ASSESSMENT WILL BE DONE ON CHANGES IN PARAMETERS OF TRICHOSCOPIC EXAMINATION IN BEFORE AND AFTER TRICHOSCOPIC IMAGES OF SAME ARIA AND SECONDARY OUTCOME ASSESSED WITH REDUCTION OF HAIR SPECIFIC SKINDEX 29 SCORE AT BASELINE AND AFTER 10 MONTHS OF TREATMENT FOLLOW UP AS PER NEED OF CASE FOR 10 MONTH OF DURATION
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 盲法
- Participant Blinded
入排标准
- 年龄范围
- 15.00 Year(s) 至 30.00 Year(s)（—）
- 性别
- Male
入选标准
- •Already diagnosed case of androgenetic alopecia up to stage III baldness of Norwood- Hamilton classification Patients who gives consent Patients who are able and understand to fill HSS29 score.
排除标准
- •Patients with scalp injury any scalp surgery Patients with past and present history of scalp lichen planus history of chronic cutaneous lupus erythematosus involving scalp and scalp eczema scalp psoriasis and inflammatory tinea capitis Patients with uncontrolled thyroid disease Patients who have taken hormone replacement therapy within past 6 months Patients with existing malignancy and history of malignancy with in the past 5 years.
结局指标
主要结局
Androgenetic alopecia will be assessed with Trichoscopic examination
时间窗: Androgenetic alopecia will be assessed at baseline and end of treatment
次要结局
- Assessed by Hair Specific Skindex 29 Score(assessed at baseline and end of treatment)
研究者
DR DIPALBEN HARSHADRAY RAVAL
Smt A J Savla Homoeopathic Medical College and Research Institute